Interferon alfacon-1


Generic Medicine Info
Contraindications
Hypersensitivity. Hepatic decompensation, autoimmune hepatitis.
Special Precautions
History of severe psychiatric disorders (monitor for signs of depression). Preexisting or history of cardiac disease. Perform periodic ophthalmologic exam in patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy). Autoimmune disorders. History of endocrine disorders. Abnormally low peripheral blood cell counts or concurrent myelosuppressive therapy. Transplantation or chronically immunosuppressed patients. Monitor haematological and thyroid functions before therapy, 2 wk after initiation and periodically thereafter. Elderly. Children (not recommended). Pregnancy, lactation. Withhold dose in patients who experience a severe adverse reaction, stop or decraese treatment if the reaction does not become tolerable.
Adverse Reactions
Insomnia, nervousness, depression, dizziness, anxiety, emotional lability; alopecia, pruritus, rash; hot flushes; GI disturbances; blood dyscrasia; inj site reactions; myalgia, arthralgia, pain, paraesthesia; flu-like symptoms; upper respiratory tract infection; chest pain, arrhythmia, MI; hypersensitivity reaction; blurred or loss of vision; hepatomegaly, liver tenderness.
Drug Interactions
Enhanced myelosuppression with other myelosuppressive drugs. Drugs metabolised via the CYP450 pathway (monitor for changes in pharmacologic or adverse effects of concomitant drug).
CIMS Class
Antivirals
ATC Classification
L03AB09 - interferon alfacon-1 ; Belongs to the class of interferons. Used as immunostimulants.
Disclaimer: This information is independently developed by CIMS based on interferon alfacon-1 from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in